COSCIENS Biopharma Inc.
CSCI.TO
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 123.08% | 32.34% | -1,200.70% | -4,160.78% | -1,811.79% |
| Total Depreciation and Amortization | -23.46% | -26.07% | -49.01% | -29.21% | -24.38% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -633.61% | -75.73% | 248.59% | 266.77% | 351.62% |
| Change in Net Operating Assets | -985.84% | 111.61% | 134.59% | -296.35% | -167.46% |
| Cash from Operations | 37.57% | 41.75% | -318.14% | -953.97% | -644.67% |
| Capital Expenditure | 92.00% | 38.85% | 37.63% | 23.23% | 9.21% |
| Sale of Property, Plant, and Equipment | 6,225.00% | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -100.00% | -100.00% | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -96.06% | -98.07% | -105.31% | 2,637.50% | 2,637.50% |
| Cash from Investing | -99.46% | -101.83% | -103.95% | -103.64% | 1,963.89% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 55.01% | 17.61% | 22.34% | 4.31% | -20.93% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 74.85% | 74.85% | -82.43% | -- | -- |
| Cash from Financing | 59.64% | 33.28% | 8.90% | -40.24% | -62.36% |
| Foreign Exchange rate Adjustments | 1,111.76% | 219.43% | 321.74% | 491.38% | -108.99% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -185.38% | -193.53% | -152.97% | -170.94% | 941.87% |